Volume 93, Issue 5, Pages (May 2018)

Slides:



Advertisements
Similar presentations
Natalie Staplin, PhD, Richard Haynes, DM, William G
Advertisements

Stephen P. McDonald, Graeme R. Russ  Kidney International 
Volume 77, Issue 12, Pages (June 2010)
Drug use and nephrotoxicity in the intensive care unit
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
End-stage renal disease in developing countries
Volume 83, Issue 3, Pages (March 2013)
Volume 93, Issue 4, Pages (April 2018)
Natalie Staplin, PhD, Richard Haynes, DM, William G
Volume 92, Issue 2, Pages (August 2017)
Kidney transplantation in a low-resource setting: Nigeria experience
Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes  Thomas Mueller,
Natalie Staplin, PhD, Richard Haynes, DM, William G
Volume 57, Issue 5, Pages (May 2000)
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)  Richard.
Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study  William.
Haiyan Wang, Luxia Zhang, Jicheng Lv  Kidney International 
Francesco Paolo Schena  Kidney International 
Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study  Martin J. Landray, PhD,
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD  Rachael L. Morton, PhD, Iryna Schlackow, DPhil, Natalie Staplin, PhD, Alastair.
Steven J. Chadban, Natalie D. Staplin  Kidney International 
End-stage renal disease in living kidney donors
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 80, Issue 9, Pages (November 2011)
Comorbidity and confounding in end-stage renal disease
Volume 63, Issue 2, Pages (February 2003)
Volume 64, Issue 1, Pages (July 2003)
Survival advantage in Asian American end-stage renal disease patients1
Volume 91, Issue 1, Pages (January 2017)
Volume 70, Issue 11, Pages (December 2006)
Volume 67, Issue 4, Pages (April 2005)
Fernando Valderrábano, Francisco Gómez-Campderá, Elizabeth H.P. Jones 
Stephen P. McDonald  Kidney International Supplements 
Volume 70, Issue 12, Pages (December 2006)
Study of Heart and Renal Protection (SHARP)
Volume 70, Issue 12, Pages (December 2006)
Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House 
American Journal of Kidney Diseases
Elevated risk of stroke among patients with end-stage renal disease
Volume 93, Issue 1, Pages (January 2018)
Racial disparities in access to transplantation: a tough nut to crack
V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen 
Volume 80, Issue 6, Pages (September 2011)
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Volume 81, Issue 9, Pages (May 2012)
Prehypertension: is it relevant for nephrologists?
Homocysteine, renal function, and risk of cardiovascular disease
Volume 77, Issue 6, Pages (March 2010)
Stephen P. McDonald, Graeme R. Russ  Kidney International 
Volume 82, Issue 3, Pages (August 2012)
The Iranian model of living renal transplantation
The Danish Renal Biopsy Register
Volume 68, Issue 1, Pages (July 2005)
Is complement a target for therapy in renal disease?
Volume 53, Issue 5, Pages (May 1998)
Volume 66, Pages S7-S10 (November 2004)
Renal replacement therapy in Latin America
Volume 87, Issue 3, Pages (March 2015)
Volume 70, Issue 5, Pages (September 2006)
Douglas E. Schaubel, Howard I. Morrison, Stanley S.A. Fenton 
Volume 77, Issue 12, Pages (June 2010)
The conundrum of increased burden of end-stage renal disease in Asians
Volume 57, Issue 2, Pages (October 2000)
Kevin C. Abbott, Robert J. Oglesby, Lawrence Y. Agodoa 
Volume 78, Issue 5, Pages (September 2010)
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Volume 60, Issue 1, Pages (July 2001)
Presentation transcript:

Volume 93, Issue 5, Pages 1165-1174 (May 2018) Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy  Benjamin C. Storey, Natalie Staplin, Charlie H. Harper, Richard Haynes, Christopher G. Winearls, Raph Goldacre, Jonathan R. Emberson, Michael J. Goldacre, Colin Baigent, Martin J. Landray, William G. Herrington  Kidney International  Volume 93, Issue 5, Pages 1165-1174 (May 2018) DOI: 10.1016/j.kint.2017.11.020 Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 1 Standardized 3-year mortality rates in newly treated end-stage renal disease (ESRD) patients and general population hospital controls. Standardized to the age, sex, and comorbidity structure of an “average” 1970 to 2008 renal replacement therapy population (see Supplementary Table S6 for characteristics). Excludes patients dying within 90 days. Year of entry is year of starting renal replacement therapy or year of relevant general population hospital controls admission. Rates plotted at midpoint of each year group. CI, confidence interval; HES, Hospital Episode Statistics. Kidney International 2018 93, 1165-1174DOI: (10.1016/j.kint.2017.11.020) Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 2 Standardized 3-year mortality rates in newly treated end-stage renal disease patients, stratified by whether patient underwent transplant within 3 years of starting renal replacement therapy. Standardized to the age, sex, and comorbidity structure of an “average” 1970 to 2008 renal replacement therapy population (see Supplementary Table S6 for characteristics). Excludes patients dying within 90 days. Year of entry is year of starting renal replacement therapy or year of relevant general population hospital controls admission. Rates plotted at midpoint of each year group. CI, confidence interval; HES, Hospital Episode Statistics. Kidney International 2018 93, 1165-1174DOI: (10.1016/j.kint.2017.11.020) Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 3 Standardized 3-year mortality rates in newly treated end-stage renal disease (ESRD) patients and general population hospital controls, stratified by prior diabetes. Standardized to the age, sex, and comorbidity structure of an “average” 1970 to 2008 RRT population (see Supplementary Table S6 for characteristics). Excludes patients dying within 90 days. Year of entry is year of starting renal replacement therapy or year of relevant general population hospital controls admission. Rates plotted at midpoint of each year group. CI, confidence interval; HES, Hospital Episode Statistics. Kidney International 2018 93, 1165-1174DOI: (10.1016/j.kint.2017.11.020) Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 4 Standardized 3-year vascular and nonvascular mortality rates in newly treated end-stage renal disease (ESRD) patients and general population hospital controls. Standardized to the age, sex, and comorbidity structure of an “average” 1970 to 2008 RRT population (see Supplementary Table S6 for characteristics). Excludes patients dying within 90 days. Year of entry is year of starting renal replacement therapy or year of relevant general population hospital controls admission. Rates plotted at midpoint of each year group. CI, confidence interval; HES, Hospital Episode Statistics. Kidney International 2018 93, 1165-1174DOI: (10.1016/j.kint.2017.11.020) Copyright © 2017 International Society of Nephrology Terms and Conditions